A thyroid medicine is being recalled at the FDA's highest risk level − and it's causing confusion and concern among the many Americans who use such medications to manage thyroid conditions. The recall ...

Mayo Clinic researchers have identified a strategy that could help chimeric antigen receptor-T cell therapy, or CAR-T cell therapy, overcome a major barrier to treating solid tumors: Cancer cells can ...

The thyroid is a butterfly-shaped gland located on the front of the neck, in front of the trachea (windpipe). Thyroid cancer happens when cells in the thyroid gland divide and change without their ...

Staging means finding out how far thyroid cancer has spread in your body. Physicians group thyroid cancer into stages I (1) through IV (4), with stage I being the least advanced and stage IV being the ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A woman who could have skipped a routine appointment eventually decided ...

A popular thyroid medicine has been recalled over concerns about its potency. Vitruvias Therapeutics Inc. has recalled one lot of its 30 mg thyroid tablets, according to a recall notice published by ...

The thyroid gland consists of two types of hormone-producing cells that regulate the body's metabolism and calcium balance. In mammals, these cell types merge into a single organ, whereas in other ...

Adjuvant pembrolizumab improves disease-free and overall survival among patients with resected clear-cell renal-cell carcinoma. The hypoxia-inducible factor 2α inhibitor belzutifan has activity in ...

Renal cell carcinoma (RCC), particularly the clear cell subtype, demonstrates a high metastatic potential and the capacity for late recurrence many years after nephrectomy. Although thyroid metastasis ...

Decnupaz offers a targeted CD123-directed therapeutic option for both treatment-naïve and R/R BPDCN, administered intravenously every 3 weeks, with significant efficacy in the frontline setting. The ...

A 69.7% composite complete response rate in newly diagnosed BPDCN patients is a striking number for a disease where oncologists have historically leaned on intensive chemotherapy regimens borrowed ...